(CercleFinance.com) – AbbVie announces that it achieved adjusted EPS of $3.31 for the fourth quarter of 2021, up 13.3%, for revenues of nearly $14.9 billion, up 7 .4% (including +7.5% operational growth).
The healthcare group thus recorded adjusted EPS up 20.3% to $12.70 over the past financial year as a whole, and declares that it anticipates this, for the year 2022, within a target range ranging from $14 to $14.20.
“We expect our diverse set of growth assets, strong pipeline and excellent execution to continue to deliver strong performance this year and over the long term,” comments CEO Richard A Gonzalez.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
